Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | GRB2 | P62993 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12475662 | 0.91 | MDM2 (0.48) | SSTR3PTPN1MDM2CTSL | |
| SCHEMBL12475679 | 0.91 | MDM2 (0.48) | SSTR3PTPN1MDM2CTSL | |
| SCHEMBL30447741 | 0.91 | MDM2 (0.47) | MDM2HDAC8 | |
| SCHEMBL26066849 | 0.91 | MDM2 (0.47) | MDM2HDAC8 | |
| SCHEMBL18683434 | 0.89 | MDM2 (0.42) | PTPN1MDM2CTSL | |
| SCHEMBL30518584 | 0.87 | PTPN1 (0.45) | PTPN1MDM2GRB2 | |
| SCHEMBL29649478 | 0.87 | SSTR3 (0.44) | SSTR3PTPN1HDAC8CTSL | |
| SCHEMBL12476855 | 0.87 | MDM2 (0.38) | PTPN1MDM2HDAC8CTSL | |
| SCHEMBL28627076 | 0.86 | SSTR3 (0.42) | SSTR3HDAC8 | |
| SCHEMBL12475854 | 0.84 | SSTR3 (0.48) | SSTR3HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968647-B2 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9968647-B2 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-05-15 | — | — | US | disclosed |
| EP-3147367-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| EP-3147367-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-26 | — | — | US | disclosed |
| EP-2658981-B1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2658981-B1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2658982-B1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-9198947-B2 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198947-B2 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9198947-B2 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140135380-A1 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135380-A1 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135380-A1 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135381-A1 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135381-A1 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135381-A1 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2012089602-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135381-A1 | Small molecule conjugates for intracellular delivery of biologically active compounds | SNRPE, PHAX, SNRPA | SSTR3 3238/4885PTPN1 3856/4885MDM2 1070/4885 |
| US-20140135380-A1 | Small molecule conjugates for intracellular delivery of nucleic acids | SNRPE, PHAX, SNRPA | SSTR3 2975/4885PTPN1 3985/4885MDM2 741/4885 |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | SNRPE, PHAX, SNRPA | SSTR3 3238/4885PTPN1 3856/4885MDM2 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.